SCHEMBL21797183

SCHEMBL21797183

CNc1nccc(-c2c(-c3ccc(F)cc3)ncn2C2CCCCC2)n1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 19/20 0.83
MAPK13 O15264 3/20 0.72
CSNK1D P48730 3/20 0.72
MAPK12 P53778 3/20 0.72
MAPK11 Q15759 3/20 0.72
EGFR P00533 2/20 0.72
CSNK1E P49674 1/20 0.72
KCNH2 Q12809 1/20 0.72
BRD4 O60885 2/20 0.61
BRDT Q58F21 2/20 0.61
BRD2 P25440 1/20 0.61
BRD3 Q15059 1/20 0.61
PRKD3 O94806 2/20 0.58
MAP4K4 O95819 2/20 0.58
LCK P06239 2/20 0.58
MAPK9 P45984 2/20 0.58
CSNK1A1 P48729 2/20 0.58
MINK1 Q8N4C8 2/20 0.58
PRKD2 Q9BZL6 2/20 0.58
MAP4K5 Q9Y4K4 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24170876 0.91 MAPK14 (1.00) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL24170595 0.91 MAPK14 (0.81) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL1640306 0.90 MAPK14 (1.00) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL24170875 0.90 MAPK14 (0.80) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL27441160 0.90 MAPK14 (1.00) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL24170872 0.89 MAPK14 (0.78) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL29841901 0.89 MAPK14 (0.82) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL28623475 0.89 MAPK14 (0.82) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL29841951 0.88 MAPK14 (0.70) MAPK14MAPK13CSNK1DMAPK12MAPK11
SCHEMBL29841960 0.88 MAPK14 (0.70) MAPK14MAPK13CSNK1DMAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3619204-B1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2025-10-01 EP disclosed
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES TIANLI BIOTECH PTY LTD (AU) 2022-12-01 US disclosed
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES THE UNIVERSITY OF MELBOURNE (AU) 2020-03-12 US disclosed
CN-110753688-A Compounds for the treatment of respiratory diseases 墨尔本大学 2020-02-04 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380343-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R MAPK14 4326/4885MAPK13 3615/4885CSNK1D 4223/4885
US-20200079757-A1 COMPOUNDS FOR THE TREATMENT OF RESPIRATORY DISEASES LTC4S, LTB4R2, LTB4R MAPK14 4326/4885MAPK13 3615/4885CSNK1D 4223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.